Organigram Posts Record Revenue, $105.5M Net Income in Q3; CFO Departs
OGI sits 17% above its 52-week low of $0.853.
Summary
Organigram delivered record Q3 results with net revenue surging 49% to $105.8M, driven by the first full quarter of contributions from the Sanity Group acquisition. Adjusted EBITDA more than doubled to $13.4M, and net income swung to a $105.5M profit from a year-ago loss, boosted by non-cash fair value gains. The Canadian business maintained #1 market share across several categories, while Sanity added roughly C$40M in net revenue and advanced European expansion. CFO and Chief Strategy Officer Paolo De Luca is departing after nine years, a notable leadership change. The strong top-line growth and profitability inflection mark a transformative quarter, though the net income includes significant non-cash items. Watch for integration progress and European market developments in the next quarter.
Updates
· SEC 6-K — The 6-K includes MD&A and unaudited interim financial statements for the three and nine months ended June 30, 2026, with net revenue of $105,782 thousand, adjusted EBITDA of $13,413 thousand, and net income of $105,538 thousand.
At the time of this announcement, OGI was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $143.3M. The 52-week trading range was $0.85 to $2.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.